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Hip fractureBackground: Information on the incidence of venous thromboembolism (VTE) following hip fractures in Asia is
rare. This study will investigate the epidemiology of symptomatic VTE in Taiwanese patients experiencing hip
fractures.
Methods and results:We used Taiwan's National Health Insurance Research Database to retrospectively iden-
tify patients (≧45 years) who experienced hip fractures from 1998 to 2007 and were followed up for 3
months after the discharge. Logistic regression analysis determined the independent risk factors of symp-
tomatic VTE after the fractures. We identiﬁed 134,034 patients (mean age: 76.2 ± 9.7 years; female:
57.8%) who experienced hip fractures, 83.2% of whom underwent hip surgery. The overall pharmacological
thromboprophylaxis rate was 2.7%. The mean length of stay was 11.3 ± 7.9 days. The 3-month cumulative
incidence of symptomatic VTE was 77 events per 10,000 persons. Multivariate analysis showed that previ-
ous DVT, previous PE, varicose veins, cancer, heart failure, renal insufﬁciency, and older age were indepen-
dent risk factors of developing VTE.
Conclusions: The incidence of symptomatic VTE after hip fractures is low in Taiwan. Patients rarely received
pharmacological thromboprophylaxis following hip fractures. Universal thromboprophylaxis for patients
experiencing hip fractures was not necessary in Taiwan, but it should be considered in high-risk populations.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Overall, hip-fracture incidence signiﬁcantly increased by 30%, from
49.6 to 64.4 per 10,000 per year from 1996 to 2002 in Taiwan [1]. Be-
cause co-morbid medical problems are common in this population,
hip fracture easily causes severe morbidity, including heart failure
(5%), acute myocardial infarction (1%), and venous thromboembolism
(2%) [2]. Additionally, the one-year mortality rate in this population
has been reported to be high (10 to 30%) in different countries [3–7].
Major orthopedic surgery, including knee and hip replacement, has
been identiﬁed as a uniformly high-risk event for VTE [8–9]. The inci-
dence of deep vein thrombosis (DVT) was about 27%, and fatal pulmo-
nary embolism oscillated between 1.4% and 7.5% of patients within 3
months of hip fracture surgery [10]. Thromboembolism prophylaxis re-
duces the rate of DVT by approximately 60% [11]. Therefore, routineability and freedom from bias of
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. This is an open access article underpharmacological thromboprophylaxis is recommended in hip fracture
surgery according to the American College of Chest Physicians (ACCP)
guideline in 2012 [12]. On the other hand, the American Association of
Orthopedic Surgeons (AAOS) suggests the use of pharmacologic agents
and/ormechanical compressive devices for the prevention of VTE in pa-
tients undergoing elective hip or knee arthroplasty, and who are not at
elevated risk beyond that of the surgery itself for VTE or bleeding [13].
For management of hip fractures in the elderly, AAOS recommends
that VTE prophylaxis should be used given the signiﬁcant established
risk factors for VTE present in this patient population, including age,
presence of hip fracture, major surgery, delays to surgery, and the po-
tential serious consequences of failure to provide prophylaxis in the
hip-fracture population [14]. Even though the ACCP guidelines are
widely adopted in Western countries and worldwide, pharmacological
thromboprophylaxis in Asia is not routine, as the incidence of VTE is
generally thought to be low and wound bleeding is a major concern.
The aim of our studywas to investigate the percentage of pharmacolog-
ical thromboprophylaxis use and the incidence of symptomatic VTE of
patients within 3 months of experiencing hip fractures. Additionally,
the secondary objective was to determine risk factors for VTE events
among these populations.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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2.1. Database
This study used claims data from the 1997–2007 National Health
Insurance Research Database (NHIRD) provided by the National
Health Research Institute in Taiwan. The NHIRD includes data on
every inpatient admission covered under the NHI program, which
has enrolled nearly 99.99% of the Taiwanese population throughout
the nation. The databases used in this study included all inpatient
and outpatient medical claims between Jan 1, 1997 and Dec 31,
2007. From the databases, we retrieved for each patient the disease
diagnosis, prescription drugs, procedures, and surgery incurred dur-
ing a hospitalization or at an outpatient visit. The study protocol con-
forms to the ethical guidelines of the 1975 Declaration of Helsinki as
reﬂected in a priori approval by the institution's human research
committee.2.2. Study design
For calculating the percentage of pharmacological thrombo-
prophylaxis in patients experiencing hip fractures and the 3-
month cumulative incidences of VTE, we identiﬁed from the above-
mentioned NHIRD 134,034 adult patients who were hospitalized
for hip fracture between Jan 1, 1998 and Sep. 30, 2007. (Fig. 1) That
admission for hip fracture was deﬁned as the index hospitalization.
Patients who were ≥45 years of age with the discharge codes of In-
ternational Classiﬁcation of Disease-Clinical Modiﬁcation, ninth re-
vision (ICD-9-CM) 820.x were all included. These patients had been
followed for 3 months after the index hospitalization, and data
were censored at the date of the VTE event, the date of death, or
the end of the follow-up period. The exclusion criteria included
(1) patients who stayed in the hospital for longer than 60 days and
(2) incomplete electronic medical records. To avoid underestimation
of fatal events from pulmonary embolism, patients who were hospi-
talized and died within 3 days without obvious etiologies were en-
rolled and regarded as fatal pulmonary embolism possibly related
to procedure.Fig. 1. The ﬂow diagram of the population-based retrospective cohort study.2.3. Comorbid diseases and potential risk factors of VTE
For each patient, we retrieved the comorbidities for VTE from both
the inpatient and outpatient claims databases for one year before and
during the index hospitalization. The comorbidities were recorded
using ICD-9-CM codes. (Supplement 1) History of VTE was deﬁned as
being hospitalized or diagnosed at an outpatient clinic with VTE before
the index hospitalization. Chronic lung disease included emphysema,
chronic bronchitis, bronchiectasis, other obstructive pulmonary disease,
and chronic respiratory failure. For neurological diseases, we only re-
corded serious illness, including stroke or other central and peripheral
nervous disease associated with extremity paresis or paralysis.
2.4. Exposure to drugs
We used prescription records to ascertain the status of drug use. In
Taiwan, anticoagulant drugs included warfarin, unfractionated heparin,
and low molecular-weight heparin (LMWH). The new oral anticoagu-
lant drugs, such as rivaroxaban and dalbigatran were not available
until 2013. Pharmacological thromboprophylaxis was deﬁned as the
new administration of any of the anticoagulant drugs during the index
hospitalization. In this study, the presence of other drugs of interest,
including statins, antiplatelet agents, and analgesics, was recorded
only if they were documented within one month preceding the index
hospitalization. The antiplatelet agents included aspirin, ticlopidine,
and clopidogrel. The analgesic agents included opioids and non-
steroidal anti-inﬂammatory drugs (NSAIDs). Hormone therapy includ-
ed the use of estrogen and/or progesterone in hormone replacement
therapy and oral contraceptives.
2.5. Study outcome
The primary study outcome was the incidence of symptomatic VTE
(deﬁned as thrombophlebitis, deep vein thrombosis, or pulmonary em-
bolism). The secondary study outcome was the composite of VTE and
overallmortalitywithin the 3-month follow-up. In our study, symptom-
atic VTE was identiﬁed from the inpatient and outpatient claims data-
base by an ICD9-CM code of 451.1×; 451.2; 451.83; 453.1; 453.2;
453.4; 453.8; 453.9; 415.1×. To avoid misdiagnoses, we selected inpa-
tients who met the following criteria: (1) the discharge diagnosis was
thrombophlebitis, DVT or PE; (2) the patient must have received a
course of subcutaneous or intravenous anticoagulation therapy with
unfractionated heparin or surgical thrombectomy during hospitaliza-
tion and continued oral warfarin therapy after discharge; and (3) the
length of staywas at least 3 days, unless the patient died.We also select-
ed outpatients whomet the following criteria: (1) the principle diagno-
siswasDVT or thrombophlebitis and (2) the patientmust have received
a course of subcutaneous anticoagulation therapywith LMWH and con-
tinued oral warfarin therapy. The same criteria were used in previous
studies that investigated VTE risk in Taiwan [15–17].
2.6. Statistical analysis
Demographic data were expressed as means (±SD) or percentages.
The cumulative incidence of VTE was determined within 3 months of
hip fracture between Jan. 1, 1998, and Sep. 30, 2007. Outcomes were
categorized as occurring during the hospitalization or after discharge
with follow-up admission to an acute-care facility with a principal
diagnosis of VTE. The primary outcomes were a principal or secondary
diagnosis of VTEwithin 3months (91 days) of the day of index hospital-
ization. We also calculated the cumulative rates of the secondary out-
comes (VTE and all-cause mortality) within 3 months after the index
hospitalization. For subgroup analysis,we calculated separately the inci-
dence of primary and secondary outcomes following the fracture. The
potential risk factors of VTE after the hip fracture were evaluated by
COX proportional hazards regression analyses. Univariate analysis was
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variate model. Variables that were signiﬁcant at the p ≦ 0.1 level in the
univariate analysis were included in themultivariate analysis. Variables
signiﬁcant at the p b 0.05 level in the Wald chi-square test in the ﬁnal
multivariate analysis were regarded as independent risk factors. We
assessed the robustness of our results based on the different lengths of
hospital stay (down to 21 days) and repeated all the same analyses, in-
cluding COX proportional hazards regression analyses, for evaluating
the predicting factors of VTE following the fractures. The hazard ratio
and associated 95% CI for the various potential risk factorswere calculat-
ed.Weused SAS statistical software (version 9.1; SAS Institute Inc., Cary,
NC) for the claims data conversion and analysis.
3. Results
3.1. Baseline characteristics and pharmacological thromboprophylaxis rate
Of the total 134,034 hospitalized patients (≧45 years) experiencing
hip fractures between Jan. 1998 and Sep. 2007, the mean age (±SD)
was 76.2 (±9.7) years old. The percentage of fractures of the femoral
neck was 60.6% and of the trochanter was 39.4%. Among these patients,
77,449 (57.8%) were women and 111,521 (83.2%) received hip surgery.
The mean length of hospitalization was 11.3 (±7.9) days. Within one
month before surgery, 22,419 (16.7%) patients received antiplatelet
agents and 79,068 (59.0%) received non-steroidal anti-inﬂammatory
drugs. The crude thromboprophylaxis rate was 2.7%, including subcuta-
neous or intravenous anticoagulant therapy (2.68%) and oral warfarin
(0.12%). There were signiﬁcantly higher percentages of co-morbid dis-
eases in patients with new VTE events compared with those without
new VTE events. However, we did not observe a signiﬁcant difference
in thromboprophylaxis rate between these two groups. (Table 1).
3.2. Clinical outcomes
During the 3-month follow-up after surgery, the overall cumulative
incidence of symptomatic VTE (n = 1034) was 77 events per 10,000Table 1
Overall clinical characteristics of hip fracture patients from Jan. 1998 to Sep. 2007.
Characteristics Overall
N = 134,034
Mean age (±SD), years 76.2 ± 9.7
Female 77,449 (57.8)
History of DVT 490 (0.4)
History of PE 193 (0.1)
Cancer 9791 (7.3)
Hypertension 86,293 (64.4)
Heart failure 22,034 (16.4)
Coronary artery disease 43,239 (32.3)
Renal insufﬁciency 26,207 (19.6)
Chronic lung disease 50,467 (37.7)
Diabetes mellitus 46,265 (34.5)
Strokea 29,485 (22.0)
Neurologic diseaseb 44,524 (33.2)
Varicose vein 932 (0.7)
Statin use 2656 (2.0)
Antiplatelet use 22,419 (16.7)
NSAID use 79,068 (59.0)
Thromboprophylaxisc 3665 (2.7)
Fracture types
Femoral neck 81,257 (60.6)
Trochanter 52,777 (39.4)
Hip surgery 111,521 (83.2)
Length of hospital stay, days 11.3 ± 7.9
Data are presented as number (percentages).
p value compared with VTE and non-VTE groups using Student's t test or χ2 test.
VTE = venous thromboembolism; DVT = deep vein thrombosis; PE = pulmonary embolism.
a Stroke includes ischemic and hemorrhagic stroke.
b Neurologic disease means stroke or other central and peripheral nervous disease with ass
c Thromboprophylaxis means in-hospital use of unfractionated heparin, low molecular weigpersons, which included 72.3% deep vein thrombosis, 22.3% pulmonary
embolism, and 5.4% coexisting deep vein thrombosis and pulmonary
embolism. Of these events, 215 (20.8%) happened during the hospitali-
zation while 819 (79.2%) had VTE after discharge. Among patients with
new VTE after discharge, most events (n= 748, 91.3%) occurred within
21 days, with a median time of diagnosis of 13.9 days after discharge.
The overall incidence of VTE was 76 events per 10,000 persons in
men and 78 events per 10,000 persons in women. In women, the inci-
dence drastically increased from 36 events per 10,000 persons in
those younger than 55 years to 80 events per 10,000 persons in those
over 75 years.We found a similar trend inmen: the incidence increased
from 51 events per 10,000 persons in those younger than 55 years to 90
events per 10,000 persons in those over 75 years (Fig. 2). In subgroup
analysis, we found that the overall cumulative rate of VTE events within
3 months after surgery was 735 events per 10,000 persons in patients
with previous DVT, 622 events per 10,000 persons with previous PE,
397 events per 10,000 persons with varicose veins, 148 events per
10,000 persons with heart failure, and 111 events per 10,000 persons
with cancer (Fig. 3). The overall cumulative rate of VTE in other
disease-speciﬁc populations was 93 events per 10,000 persons with
chronic lung diseases, 80 events per 10,000 persons with diabetes
mellitus, 107 events per 10,000 persons with coronary heart disease,
and 111 events per 10,000 persons with renal insufﬁciency. The cumu-
lative VTE incidence in patients undergoing hip surgery was lower than
those not receiving surgery (74 vs 95 events per 10,000 persons, p =
0.001). The overall cumulative mortality rate was 8.3% (n = 11,125)
up to 3months after surgery. Patients with history of PE (19.6%), cancer
(15.2%), heart failure (14.8%), coronary artery disease (11.2%), and var-
icose veins (10.8%) had higher mortality rates than overall populations
of the study. (Fig. 3).
3.3. Predictors for venous thromboembolism
Potential VTE risk factors were prior DVT (0.4%), prior PE (0.1%),ma-
lignancy (7.3%), serious neurologic disease (33.2%), heart failure
(16.4%), and varicose veins (0.7%). Univariate analysis showed thatVTE
N = 1034
Non-VTE
N = 133,000
p value
76.9 ± 9.0 76.2 ± 9.7 0.016
604 (58.4) 76,845 (57.8) 0.681
36 (3.5) 454 (0.3) b0.001
12 (1.2) 181 (0.1) b0.001
109 (10.5) 9682 (7.3) b0.001
744 (72.0) 85,549 (64.3) b0.001
326 (31.5) 21,708 (16.3) b0.001
461 (44.6) 42,778 (32.2) 0.025
290 (28) 25,917 (19.5) b0.001
470 (45.5) 49,997 (37.6) 0.294
370 (35.8) 45,895 (34.5) 0.393
243 (23.5) 29,242 (22.0) 0.243
363 (35.1) 44,161(33.2) 0.196
37 (3.6) 895 (0.7) b0.001
34 (2.5) 2622 (2.9) 0.606
260 (19.4) 22,159 (12.3) b0.001
523 (50.6) 78,543 (59.1) b0.001
5 (2.5) 3660 (2.8) 0.575
581 (56.2) 80,676 (60.7) 0.004
453 (43.8) 52,324 (39.3) 0.004
820 (79.3) 110,701 (83.2) 0.001
12.9 ± 9.5 11.3 ± 7.9 b0.001
ociated extremity paresis or paralysis.
ht heparin, or warfarin.
Fig. 2. The incidence of venous thromboembolism among various age and gender groups in Taiwan from 1998 to 2007.
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as history of VTE, cancer, cardiovascular diseases, renal insufﬁciency, se-
rious neurologic diseases, and varicose veins, in patients with new VTE
events than those without VTE events (Table 1). In primary analysis,
several baseline characteristics and potential risk factors were com-
pared between the VTE and non-VTE groups by COX proportional haz-
ards regression analyses (Table 2). Although the VTE incidence in
patients undergoing hip surgery was lower than in patients who did
not undergo surgery, hip surgery was not an independent risk factor
of VTE occurrence after using hazards regression analyses. We thought
that patients who did not receive surgery had more complex co-
morbid diseases than those who received surgery. Therefore, lower
VTE incidence in patients undergoing surgery may be due to less com-
plex underlying diseases. (Supplement 2) In our study, previous DVT
(hazard ratio (HR) 8.62, 95% conﬁdence interval (CI) 5.95–12.66), previ-
ous PE (HR 4.59, 95% CI 2.41–8.77), varicose veins (HR5.01, 95% CI 3.56–
6.99)malignant neoplasm(HR 1.42, 95% CI 1.16–1.74), heart failure (HR
1.87, 95% CI 1.62–2.16), renal insufﬁciency (HR 1.29, 95% CI 1.12–1.49),
and older age (HR 1.08, 95% CI 1.02–1.16)were independent risk factors
for developing VTE (Table 2).
The percentages of clinical morbidities did not change appreciably
when we redeﬁned the length of hospital stay shortening it to
21 days. (Supplement 3) As expected, the results of predictors for
fracture-related VTE were virtually unchanged when we performed
multivariate logistic regression analysis (Table 2).Fig. 3. Cumulative incidences of VTE admission and/or deaths among different patient groups f
heart failure; ND, neurologic disorder with extremity paralysis or paresis; VV, varicose veins; C4. Discussion
Nowadays, it is almost impossible to conduct a nationwide
population-based cohort study to observe the natural course of VTE
among hip-fracture patients awaiting surgery with a rather low rate of
pharmacological thromboprophylaxis in Western countries because
pharmacological thromboprophylaxis would be routinely given in
these populations. This study was a 10-year nationwide population-
based observational cohort study to estimate the pharmacological
thromboprophylaxis rate in patients experiencing hip fractures and
the incidence of symptomatic VTE within a 3-month follow-up.
The main ﬁndings were as follows: (1) the rate of pharmacological
thromboprophylaxis was very low (2.7%) in these patients; (2) among
the 134,034 patients, the 3-month cumulative incidence of symptomat-
ic VTE following hip fractures was only 77 events per 10,000 persons;
(3) previous VTE, malignancy, heart failure, varicose veins, and chronic
kidney disease were associated with higher risks of VTE occurrence
following hip fractures; (4) most VTE events (79.2%) occurred after
discharge, with a median time of 13.9 days between discharge and
diagnosis.
VTE is a major public health concern in Western countries. The esti-
mated annual incidence is 71 to 133 cases per 100,000 persons [18–20].
DVT is one of the principal causes of perioperative morbidity and mor-
tality in hip fracture patients. Without thromboembolism prophylaxis,
the prevalence of venography-detected proximal DVT rises to 27% ofollowing hip fractures. DVT denotes deep vein thrombosis; PE, pulmonary embolism; HF,
AD, coronary artery disease.
Table 2
Results of COX proportional hazards regression analyses of potential risk factors of symp-
tomatic venous thromboembolism.a
Variables Primary analysis
Hazard ratio (95% CI),
p value
Additional analysisa
Hazard ratio (95% CI),
P value
Deep vein thrombosis
history
8.62 (5.95–12.66), b0.001 7.83 (5.17–11.85), b0.001
Pulmonary embolism
history
4.59 (2.41–8.77), b0.001 4.65 (2.28–9.52), b0.001
Cancer 1.42 (1.16–1.74), 0.001 1.44 (1.16–1.79), 0.001
Varicose veins 5.01 (3.56–6.99), b0.001 4.59 (3.18–6.62), b0.001
Heart failure 1.87 (1.62–2.16), 0.029 1.95 (1.67–2.27), b0.001
Renal insufﬁciency 1.29 (1.12–1.49), b0.001 1.38 (1.18–1.61), b0.001
Age 1.08 (1.02–1.18), 0.005 1.03 (1.01–1.16), 0.006
⁎Neurologic disease 1.01 (0.88–1.16), 0.892 1.02 (0.87–1.21), 0.875
Hypertension 1.14 (0.99–1.32), 0.072 1.08 (0.92–1.26), 0.340
Hip surgery 0.98 (0.84–1.15), 0.833 1.04 (0.87–1.25), 0.664
Coronary artery disease 1.13 (0.68–1.49), 0.894 1.09 (0.72–1.56), 0.879
Pharmacological VTE
prophylaxis
0.81 (0.55–1.21), 0.304 0.85 (0.67–1.23), 0.487
⁎ Neurologic diseasemeans stroke or other central and peripheral nervous diseasewith
associated extremity paresis or palalysis.
a We repeated COX proportional hazards regression analyses based on the different
lengths of hospital stay (down to 21 days).
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tween 1.4% to 7.5% within 3 months of hip-fracture surgery [10]. Throm-
boembolism prophylaxis reduces the rate of DVT by approximately 60%
[11]. The AAOS guidelines for the prevention of VTE in patients undergo-
ing hip or knee surgery conﬂict with ACCP guidelines [21,22]. Both guide-
lines accepted that the most important goal of thromboprophylaxis in
patients undergoing hip fracture surgery is to prevent PE. The ACCP
guidelines included asymptomatic and symptomatic DVT detected by ve-
nography as a measure of the efﬁcacy of thromboprophylaxis, whereas
theAAOSdidnot regardDVT as a valid indicator because the link between
DVT and PEwas unproven. However, these studies weremostly conduct-
ed among Caucasian populations. The incidence of VTE in Taiwan and
other Asian countries is much lower than in Western countries [15,23–
25], even though pharmacological thromboprophylaxis is not yet a
routine practice in Asia, even in high-risk surgical situations [16,26–30].
Particularly, our previous nationwide population-based study shows
that the crude incidence of VTE is only 15.9 cases per 100,000 persons
[15]. In addition, our serial studies found out that the pharmacological
thromboprophylaxis rate was 2.2–3.0% and the 3-month cumulative inci-
dence of symptomatic VTE was 0.41–0.46% in patients undergoing major
orthopedic surgery [16,17]. In the SMART study [29–30], the pharmaco-
logical thromboprophylaxis rate was only 3.6% in patients undergoing
major orthopedic surgery. Although the incidence of asymptomatic VTE
was 35.6% during the hospitalization, the incidence of symptomatic VTE
and sudden death within a one-month follow-up was only 1.5%. We
could not obtain the asymptomatic VTE incidence rate in our populations,
but the all-cause mortality in our study (8.3%) was at the lower end as
compared with previous ones (8–20% at 3 months) [31–33]. Based on
the SMART and our study, it is very likely that most asymptomatic VTE
events developing after major orthopedic surgery regress spontaneously
in Asian patients without pharmacological intervention. Our results sup-
port the viewpoint of the AAOS guidelines that the link between DVT
and PE is uncertain in these populations.
We observed the time course of developing symptomatic VTE in hip
fracture patients. Among patients who developed symptomatic VTE,
20.8% occurred during hospitalization and 79.2% had VTE after dis-
charge. Among patients with new VTE after discharge, most events
(91.3%) occurred within 21 days, with a median time of diagnosis of
13.9 days after discharge. Although the incidence of symptomatic VTE
was much lower in Taiwan than in Western countries, the time course
of developing symptomatic VTE in these populations was very similar.
White and colleagues reported that the median time of diagnosis ofsymptomatic VTE was about 17 days in patients undergoing major hip
surgery [34]. These ﬁndings suggest that orthopedic surgeons should
be aware of patients' signs of VTE within 2–3 weeks after discharge
and, in high-risk Taiwanese patients experiencing hip fractures, the
use of pharmacological thromboprophylaxis should be extended from
the hospital stay to at least 2 weeks after discharge.
Likewise, previous studies showed that prior VTE [35], female gender
[34], age over 70 years [19,36], body mass index (BMI) over 25 [37], and
longer duration of immobilization [38] are important risk factors for de-
velopment of symptomatic VTE among patients undergoing major
arthroplasty. In the current study, we identiﬁed some similar risk factors
of VTE following hip fracture surgery, such as prior VTE and older age.
We also identiﬁed varicose veins, heart failure, cancer, and renal insufﬁ-
ciency as risk factors of VTE. Although we have observed lower risk of
VTE occurrence in patients receiving hip surgery than those without hip
surgery, we found that the hip surgery itself did not increase the risk of
VTE in these populations because patients undergoing surgery were
younger and had lower percentages of co-morbidities than thosewithout
surgery. The complexity of underlying diseases determined the risk of
VTE. The proportion of patients who received pharmacological prophy-
laxis was only 2.7% in this study. A beneﬁcial effect of pharmacological
thromboprophylaxis was not observed. We attributed this neutral effect
of pharmacological thromboprophylaxis to the small sample size of pa-
tients who received the prevention and the non-selective population
without other risk factors. Further randomized controlled study is war-
ranted to examine the effect of pharmacological thromboprophylaxis in
Taiwanese hip-fracture patients with other identiﬁed VTE risk factors.
Our ﬁndings have several clinical implications for Asian populations.
First, although the rate of pharmacological thromboprophylaxis was
very low in hip fracture patients in Taiwan, symptomatic VTE rarely de-
veloped. One prospective Asian study (SMART study) showed that the
pharmacological thromboprophylaxis rate was only 3.6% in patients un-
dergoing major orthopedic surgery, but the incidence of VTE and sudden
death at a month's follow-up was only 1.5% [29,30]. However, our ﬁnd-
ings suggest that adequate pharmacological thromboprophylaxis around
hip fractures in high-risk populations, especially those with VTE history,
may reduce new VTE events. Most VTE events develop within 3 weeks
after the discharge; therefore, patients should be educated to becomemo-
bile as soon as possible and surgeons should be alert if persistent swelling
of the compromised extremity suggests deep vein thrombosis.
There are several limitations in the present investigation. First, the
healthcare claims data inherently contains potential disease misclassiﬁ-
cation bias. However, the auditingmechanism conducted by the Bureau
of National Health Insurancewould help tominimize the diagnostic un-
certainty andmisclassiﬁcation in claims databases. Second, whether the
patient received pneumatic compression after the surgery was indeter-
minate. Third, the true incidence of VTE following hip fractures in
Taiwan may be underestimated because some patients with PE may
die suddenly without accurate diagnosis and some symptomatic
VTE patients may be treated as surgery-related leg edema. To avoid
underestimating fatal pulmonary embolism, we also calculated the all-
cause mortality within 3 months after the discharge. Given the 3-
month mortality rate was 8.3% and similar to previousWestern studies,
the bias should be low. Finally, surgical procedure time, smoking histo-
ry, and body mass index were not available in the databases.
In conclusion, the rate of pharmacological thromboprophylaxis is
very low in Taiwan, whichmay be related to the low incidence of symp-
tomatic VTE after hip fractures. Although universal pharmacological
thromboprophylaxis is not recommended generally in Taiwan, it should
be considered in high-risk populations that include a history of VTE,ma-
lignancy, heart failure, varicose veins, and chronic kidney disease.
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